Retrospective review reveals logistical challenges and IVIG needs in pediatric B-ALL patients receiving blinatumomab, suggesting delivery method adaptations.
Blinatumomab, a CD19xCD3 bispecific T-cell engager, has become standard therapy for children with de novo B-cell acute lymphoblastic leukemia (B-ALL). This retrospective review describes the experience of blinatumomab administration in pediatric patients. At our institution, 31 children with B-ALL received continuous intravenous (IV) blinatumomab from January 1, 2018, to December 31, 2024. Logistical issues requiring clinical intervention occurred in 16 (51.6%) patients, with 57.8% of these issues resulting in hospitalization. After receiving blinatumomab, 26 patients (83.9%) required intravenous immunoglobulin (IVIG). These results support investigations into alternative methods of blinatumomab delivery and the impact of blinatumomab on immune function in pediatric patients with B-ALL.
No takes yet. Share an insight, caveat, or question.
Hurley et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: